Mostrando las entradas con la etiqueta diabetes mellitus. Mostrar todas las entradas
Mostrando las entradas con la etiqueta diabetes mellitus. Mostrar todas las entradas

domingo, 30 de agosto de 2009

El uso de la hemoglobina A1C para el diagnostico de Diabetes.

une 7, 2009 (New Orleans, Louisiana) — The American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) have joined forces to recommend the use of the hemoglobin A1C assay for the diagnosis of diabetes.

The international expert committee's recommendations were announced here on Friday during the opening hours of the ADA's 69th Scientific Sessions and released simultaneously online in the July issue of Diabetes Care.

"This is the first major departure in 30 years in diabetes diagnosis," committee chairman David M. Nathan, MD, director of the Diabetes Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School in Boston, declared in presenting the committee's findings.

"A1C values vary less than FPG [fasting plasma glucose] values and the assay for A1C has technical advantages compared with the glucose assay," Dr. Nathan said. A1C gives a picture of the average blood glucose level over the preceding 2 to 3 months, he added.

"A1C has numerous advantages over plasma glucose measurement," Dr. Nathan continued. "It's a more stable chemical moiety.... It's more convenient. The patient doesn't need to fast, and measuring A1C is more convenient and easier for patients who will no longer be required to perform a fasting or oral glucose tolerance test.... And it is correlated tightly with the risk of developing retinopathy."

A disadvantage is the cost. "It is more expensive," Dr. Nathan acknowledged. However, cost analyses have not been done, "...and costs are not the same as charges [to the patient]."

The committee has determined that an A1C value of 6.5% or greater should be used for the diagnosis of diabetes.

This cut-point, Dr. Nathan said, "is where risk of retinopathy really starts to go up."

He cautioned that there is no hard line between diabetes and normoglycemia, however, "...an A1C level of 6.5% is sufficiently sensitive and specific to identify people who have diabetes."

"We support the conclusion of the committee, that this is an appropriate way to diagnose diabetes," stated Paul Robertson, MD, president of medicine and science at the ADA and professor of medicine at the University of Washington in Seattle.

"Now, we have to refer the committee's findings to practice groups for review of the implications and for recommendations," Dr. Robertson told Medscape Diabetes & Endocrinology after the committee's presentation.

"We purposely avoided using estimated average glucose, or EAG, as this is just a way to convert the A1C into glucose levels.... And one thing we want to try to get away from is the term prediabetes," Dr. Nathan said. "It suggests that people with it will go on to get diabetes, but that is not the case."

"We don't know if we will be diagnosing more patients with diabetes or less, with AIC," Dr. Nathan commented. Cut-off values or practice guidelines have not been established. More study needs to be done first, but "physicians should not mix and match A1C and blood glucose levels. They should stick with one in reviewing a patient's history," Dr. Nathan asserted.

"There is no gold standard assay," said session moderator Richard Kahn, PhD, chief medical and scientific officer of the ADA, which is headquartered in Alexandria, Virginia. "All of these tests measure different things. They all have value. But A1C is the best test to assess risk of retinopathy."

"We [the ADA] are not issuing a position statement at this time," Dr. Robertson stressed when speaking withMedscape Diabetes & Endocrinology. "It is too soon to write a position paper yet. We need to know what we are getting into first."

"Some parts of the world are not going to be able to use this," Dr. Robertson added. "It may be too expensive to use in the developing world. Some of these countries have severe chronic anemia, hemolytic anemia, and so on, where we will have to fall back on traditional tests. We are being very cognizant of the international implications." A1C assays are inaccurate in cases of severely low hemoglobin levels.

"We don't think physicians will have a hard time adopting the test...a lot of them are doing it already. We think it will only take a couple of years to be adopted widely into clinical practice," Dr. Kahn told Medscape Diabetes & Endocrinology. "Physicians won't be shocked by this report, but patients — and insurance companies — might be. There are wider social issues that haven't been looked at yet."

None of the speakers at this session disclosed any relevant financial relationships.

American Diabetes Association (ADA) 69th Scientific Sessions. Presented June 5, 2009.

Diabetes Care. Published online June 5, 2009.

TEl uso de

martes, 25 de agosto de 2009

Hipogonadismo Hipogonadotropico en Diabetesw tipo 2,Obesidad y sindrome metabolico

1: Curr Mol Med. 2008 Dec;8(8):816-28.Links

Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome.

Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, NY 14209, USA. pdandona@kaleidahealth.org

Recent work shows a high prevalence of low testosterone and inappropriately low LH and FSH concentrations in type 2 diabetes. This syndrome of hypogonadotrophic hypogonadism (HH) is associated with obesity, and other features of the metabolic syndrome (obesity and overweight, hypertension and hyperlipidemia) in patients with type 2 diabetes. However, the duration of diabetes or HbA1c were not related to HH. Furthermore, recent data show that HH is also observed frequently in patients with the metabolic syndrome without diabetes but is not associated with type 1 diabetes. Thus, HH appears be related to the two major conditions associated with insulin resistance: type 2 diabetes and the metabolic syndrome. CRP concentrations have been shown to be elevated in patients with HH and are inversely related to plasma testosterone concentrations. This inverse relationship between plasma free testosterone and CRP concentrations in patients with type 2 diabetes suggests that inflammation may play an important role in the pathogenesis of this syndrome. This is of interest since inflammatory mechanisms may have a cardinal role in the pathogenesis of insulin resistance. It is relevant that in the mouse, deletion of the insulin receptor in neurons leads to HH in addition to a state of systemic insulin resistance. It has also been shown that insulin facilitates the secretion of gonadotrophin releasing hormone (GnRH) from neuronal cell cultures. Thus, HH may be the result of insulin resistance at the level of the GnRH secreting neuron. Low testosterone concentrations in type 2 diabetic men have also been related to a significantly lower hematocrit and thus to an increased frequency of mild anemia. Low testosterone concentrations are also related to an increase in total and regional adiposity, and to lower bone density. This review discusses these issues and attempts to make the syndrome relevant as a clinical entity. Clinical trials are required to determine whether testosterone replacement alleviates symptoms related to sexual dysfunction, and features of the metabolic syndrome, insulin resistance and inflammation.

PMID: 19075678 [PubMed - indexed for MEDLINE]

Hormona sexual ligada a globulina y riesgo de Diabetes tipo II en Mujeres y Hombres

1: N Engl J Med. 2009 Aug 5. [Epub ahead of print]Click here to read Links

Sex Hormone-Binding Globulin and Risk of Type 2 Diabetes in Women and Men.

From the Departments of Nutrition (E.L.D., D.J.H.) and Epidemiology (E.L.D., J.E.M., D.J.H., J.E.B.), Harvard School of Public Health; the Division of Preventive Medicine (E.L.D., Y.S., J.E.M., J.E.B., J.M.G.), Channing Laboratory (E.L.D., J.E.M., D.J.H.), and the Division of Aging (J.M.G.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; the Department of Laboratory Medicine, Children's Hospital and Harvard Medical School (N.R.); and Massachusetts Veterans Epidemiology Research and Information Center, Veterans Affairs (VA) Boston Healthcare System (J.M.G.) - all in Boston; and VA Greater Los Angeles Healthcare System (C.C.L.); the Department of Epidemiology, Program on Genomics and Nutrition and Center for Metabolic Disease Prevention, UCLA School of Public Health (C.C.L., S.L.); the Department of Medicine, UCLA David Geffen School of Medicine (C.C.L., S.L.); and Jonsson Comprehensive Cancer Center, UCLA (S.L.) - all in Los Angeles. Drs. Ding and Song contributed equally to this article.This article (10.1056/NEJMoa0804381) was published on August 5, 2009, at NEJM.org.

BACKGROUND: Circulating sex hormone-binding globulin levels are inversely associated with insulin resistance, but whether these levels can predict the risk of developing type 2 diabetes is uncertain. METHODS: We performed a nested case-control study of postmenopausal women in the Women's Health Study who were not using hormone therapy (359 with newly diagnosed type 2 diabetes and 359 controls). Plasma levels of sex hormone-binding globulin were measured; two polymorphisms of the gene encoding sex hormone-binding globulin, SHBG, that were robustly associated with the protein levels were genotyped and applied in mendelian randomization analyses. We then conducted a replication study in an independent cohort of men from the Physicians' Health Study II (170 with newly diagnosed type 2 diabetes and 170 controls). RESULTS: Among women, higher plasma levels of sex hormone-binding globulin were prospectively associated with a lower risk of type 2 diabetes: multivariable odds ratios were 1.00 for the first (lowest) quartile of plasma levels, 0.16 (95% confidence interval [CI], 0.08 to 0.33) for the second quartile, 0.04 (95% CI, 0.01 to 0.12) for the third quartile, and 0.09 (95% CI, 0.03 to 0.21) for the fourth (highest) quartile (P<0.001 p="0.005)," p="0.004);">

PMID: 19657112 [PubMed - as supplied by publisher]

El efecto protector de la Diabetes mellitus,contra el Cáncer de próstata,rol de las Hormonas sexuales.

1: Prostate. 2009 Aug 12. [Epub ahead of print]Click here to read Links

The protective effect of diabetes mellitus against prostate cancer: Role of sex hormones.

Department of Urology, Urology Research Center, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.

BACKGROUND: Diabetes mellitus (DM) has been associated with decreased risk of prostate cancer (PC) in several reports. Hormonal environment of diabetic patients is believed to be an important contributing factor in this regard. METHODS: Using data from a multi-center case-control study in Iran, base line testosterone, sex hormone binding globulin (SHBG), estradiol, and albumin levels as well as thorough demographic and medical characteristics of 194 newly diagnosed prostate cancer patients were determined. There were 317 ethnicity-matched men with no cancer as controls as well. Data was analyzed for hormones of interest in DM patients regarding their cancer status. RESULTS: Of 511 enrolled patients, twenty-one cases and 63 controls were diagnosed as DM. Patients with DM were significantly less likely to have PC (OR: 0.44, P = 0.003). Time since DM diagnosis was also inversely correlated with the risk of cancer (P trend <>

PMID: 19676082 [PubMed - as supplied by publisher]

clitorisvaginavejigasalud

Bookmark and Share

hormonas yosteoporosis en el hombre

Bookmark and Share